a public good project by the
Synthesis
Company
of California

© 2026

Valter Torri | doi.page

0 works0 citations0 h-index

Valter Torri

Mario Negri Institute for Pharmacological Research(IT)

Publications by Year

Research Areas

Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Ovarian cancer diagnosis and treatment, HER2/EGFR in Cancer Research

Most-Cited Works

→ Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints(1998)4,805 cited
→ Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group(2008)2,629 cited
→ Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer(2010)1,600 cited
→ Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial(2008)1,541 cited
→ Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial(2003)1,195 cited
→ Duration of Adjuvant Chemotherapy for Stage III Colon Cancer(2018)

1,100 cited

→ Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial(2016)993 cited

→ Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials(1998)833 cited

→ COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study(2020)622 cited

→ Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial(2016)590 cited